vs
CENTERSPACE（CSR）与再鼎医药（ZLAB）财务数据对比。点击上方公司名可切换其他公司
再鼎医药的季度营收约是CENTERSPACE的1.9倍（$127.1M vs $66.6M），再鼎医药同比增速更快（17.1% vs 0.3%），CENTERSPACE自由现金流更多（$64.3M vs $-26.7M），过去两年再鼎医药的营收复合增速更高（20.8% vs 1.6%）
Centerspace是一家专注于多户住宅物业持有、运营与开发的房地产投资企业，核心业务覆盖美国中西部及落基山西部区域，面向不同租户群体提供经济型及高端住宅选择，重视租户体验与资产长期价值增长。
再鼎医药是一家创新生物制药企业，专注于肿瘤、自身免疫性疾病、感染性疾病等领域创新疗法的研发、生产与商业化，核心市场覆盖大中华区，与全球多家头部生物科技企业合作，为存在未被满足医疗需求的患者提供治疗方案。
CSR vs ZLAB — 直观对比
营收规模更大
ZLAB
是对方的1.9倍
$66.6M
营收增速更快
ZLAB
高出16.8%
0.3%
自由现金流更多
CSR
多$91.0M
$-26.7M
两年增速更快
ZLAB
近两年复合增速
1.6%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $66.6M | $127.1M |
| 净利润 | $-18.4M | — |
| 毛利率 | 96.5% | 51.0% |
| 营业利润率 | -15.9% | -54.6% |
| 净利率 | -27.7% | — |
| 营收同比 | 0.3% | 17.1% |
| 净利润同比 | -262.9% | — |
| 每股收益（稀释后） | $-1.08 | $-0.05 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CSRZLAB
| Q4 25 | $66.6M | $127.1M | ||
| Q3 25 | $71.4M | $115.4M | ||
| Q2 25 | $68.5M | $109.1M | ||
| Q1 25 | $67.1M | $105.7M | ||
| Q4 24 | $66.4M | $108.5M | ||
| Q3 24 | $65.0M | $101.8M | ||
| Q2 24 | $65.0M | $100.1M | ||
| Q1 24 | $64.5M | $87.1M |
净利润CSRZLAB
| Q4 25 | $-18.4M | — | ||
| Q3 25 | $53.8M | $-36.0M | ||
| Q2 25 | $-14.5M | $-40.7M | ||
| Q1 25 | $-3.7M | $-48.4M | ||
| Q4 24 | $-5.1M | — | ||
| Q3 24 | $-1.0M | $-41.7M | ||
| Q2 24 | $-1.3M | $-80.3M | ||
| Q1 24 | $-3.9M | $-53.5M |
毛利率CSRZLAB
| Q4 25 | 96.5% | 51.0% | ||
| Q3 25 | 96.5% | 59.5% | ||
| Q2 25 | 96.5% | 60.6% | ||
| Q1 25 | 96.4% | 63.6% | ||
| Q4 24 | 96.5% | 61.5% | ||
| Q3 24 | 96.6% | 64.1% | ||
| Q2 24 | 96.6% | 64.9% | ||
| Q1 24 | 96.4% | 61.4% |
营业利润率CSRZLAB
| Q4 25 | -15.9% | -54.6% | ||
| Q3 25 | — | -42.3% | ||
| Q2 25 | -9.9% | -50.3% | ||
| Q1 25 | 7.1% | -53.3% | ||
| Q4 24 | 4.3% | -62.6% | ||
| Q3 24 | 9.8% | -66.6% | ||
| Q2 24 | 11.1% | -76.0% | ||
| Q1 24 | 6.3% | -80.7% |
净利率CSRZLAB
| Q4 25 | -27.7% | — | ||
| Q3 25 | 75.3% | -31.2% | ||
| Q2 25 | -21.2% | -37.3% | ||
| Q1 25 | -5.6% | -45.8% | ||
| Q4 24 | -7.6% | — | ||
| Q3 24 | -1.6% | -40.9% | ||
| Q2 24 | -2.0% | -80.2% | ||
| Q1 24 | -6.1% | -61.4% |
每股收益（稀释后）CSRZLAB
| Q4 25 | $-1.08 | $-0.05 | ||
| Q3 25 | $3.19 | $-0.03 | ||
| Q2 25 | $-0.87 | $-0.04 | ||
| Q1 25 | $-0.22 | $-0.04 | ||
| Q4 24 | $-0.31 | $-0.09 | ||
| Q3 24 | $-0.40 | $-0.04 | ||
| Q2 24 | $-0.19 | $-0.08 | ||
| Q1 24 | $-0.37 | $-0.05 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $12.8M | $689.6M |
| 总债务越低越好 | $1.0B | — |
| 股东权益账面价值 | $719.2M | $715.5M |
| 总资产 | $1.9B | $1.2B |
| 负债/权益比越低杠杆越低 | 1.42× | — |
8季度趋势，按日历期对齐
现金及短期投资CSRZLAB
| Q4 25 | $12.8M | $689.6M | ||
| Q3 25 | $12.9M | $717.2M | ||
| Q2 25 | $12.4M | $732.2M | ||
| Q1 25 | $11.9M | $757.3M | ||
| Q4 24 | $12.0M | $779.7M | ||
| Q3 24 | $14.5M | $616.1M | ||
| Q2 24 | $14.3M | $630.0M | ||
| Q1 24 | $12.7M | $650.8M |
总债务CSRZLAB
| Q4 25 | $1.0B | — | ||
| Q3 25 | $1.1B | — | ||
| Q2 25 | $1.1B | — | ||
| Q1 25 | $955.5M | — | ||
| Q4 24 | $955.4M | — | ||
| Q3 24 | $921.3M | — | ||
| Q2 24 | $931.7M | — | ||
| Q1 24 | $929.1M | — |
股东权益CSRZLAB
| Q4 25 | $719.2M | $715.5M | ||
| Q3 25 | $748.6M | $759.9M | ||
| Q2 25 | $710.1M | $791.7M | ||
| Q1 25 | $636.8M | $810.8M | ||
| Q4 24 | $752.0M | $840.9M | ||
| Q3 24 | $672.5M | $667.7M | ||
| Q2 24 | $680.7M | $704.2M | ||
| Q1 24 | $688.1M | $762.2M |
总资产CSRZLAB
| Q4 25 | $1.9B | $1.2B | ||
| Q3 25 | $2.1B | $1.2B | ||
| Q2 25 | $2.0B | $1.2B | ||
| Q1 25 | $1.9B | $1.2B | ||
| Q4 24 | $1.9B | $1.2B | ||
| Q3 24 | $1.9B | $985.3M | ||
| Q2 24 | $1.9B | $987.4M | ||
| Q1 24 | $1.9B | $988.4M |
负债/权益比CSRZLAB
| Q4 25 | 1.42× | — | ||
| Q3 25 | 1.53× | — | ||
| Q2 25 | 1.57× | — | ||
| Q1 25 | 1.50× | — | ||
| Q4 24 | 1.27× | — | ||
| Q3 24 | 1.37× | — | ||
| Q2 24 | 1.37× | — | ||
| Q1 24 | 1.35× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $98.5M | $-26.0M |
| 自由现金流经营现金流 - 资本支出 | $64.3M | $-26.7M |
| 自由现金流率自由现金流/营收 | 96.5% | -21.0% |
| 资本支出强度资本支出/营收 | 51.3% | 0.5% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $125.9M | $-158.9M |
8季度趋势，按日历期对齐
经营现金流CSRZLAB
| Q4 25 | $98.5M | $-26.0M | ||
| Q3 25 | $35.1M | $-32.0M | ||
| Q2 25 | $25.3M | $-31.0M | ||
| Q1 25 | $25.4M | $-61.7M | ||
| Q4 24 | $98.2M | $-55.8M | ||
| Q3 24 | $32.3M | $-26.8M | ||
| Q2 24 | $22.9M | $-42.2M | ||
| Q1 24 | $24.4M | $-90.1M |
自由现金流CSRZLAB
| Q4 25 | $64.3M | $-26.7M | ||
| Q3 25 | $25.7M | $-35.0M | ||
| Q2 25 | $15.5M | $-33.9M | ||
| Q1 25 | $20.4M | $-63.2M | ||
| Q4 24 | $41.6M | $-58.4M | ||
| Q3 24 | $20.5M | $-28.2M | ||
| Q2 24 | $9.1M | $-42.9M | ||
| Q1 24 | $2.6M | $-91.1M |
自由现金流率CSRZLAB
| Q4 25 | 96.5% | -21.0% | ||
| Q3 25 | 36.0% | -30.4% | ||
| Q2 25 | 22.7% | -31.1% | ||
| Q1 25 | 30.4% | -59.9% | ||
| Q4 24 | 62.6% | -53.8% | ||
| Q3 24 | 31.5% | -27.7% | ||
| Q2 24 | 14.0% | -42.9% | ||
| Q1 24 | 4.0% | -104.5% |
资本支出强度CSRZLAB
| Q4 25 | 51.3% | 0.5% | ||
| Q3 25 | 13.1% | 2.6% | ||
| Q2 25 | 14.2% | 2.6% | ||
| Q1 25 | 7.5% | 1.5% | ||
| Q4 24 | 85.3% | 2.4% | ||
| Q3 24 | 18.2% | 1.3% | ||
| Q2 24 | 21.2% | 0.7% | ||
| Q1 24 | 33.8% | 1.1% |
现金转化率CSRZLAB
| Q4 25 | — | — | ||
| Q3 25 | 0.65× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CSR
| Multi Family Residential | $57.3M | 86% |
| Other | $8.1M | 12% |
| Other Property Revenue | $1.2M | 2% |
ZLAB
| Zejula | $56.0M | 44% |
| Other | $21.9M | 17% |
| Nuzyra | $16.0M | 13% |
| Optune | $11.9M | 9% |
| XACDURO | $10.7M | 8% |
| Qinlock | $9.7M | 8% |
| AUGTYRO | $836.0K | 1% |
